市場調查報告書
商品編碼
921238

炭疽病治療藥的全球市場:成長,趨勢,及預測

Anthrax Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

出版日期: | 出版商: Mordor Intelligence Pvt Ltd | 英文 111 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

由於增加了研究經費和開發了新的炭疽治療方法,炭疽藥物的全球市場正在迅速增長。平民和軍隊中炭疽病的威脅越來越大,導致開發了新的炭疽病治療方法。增加官民合作關係以促進炭疽病的創新和有效治療方法的新發展是有望推動市場增長的因素之一。

本報告提供全球炭疽病治療藥市場的相關調查,提供市場機會和趨勢,成長及阻礙因素,各炭疽病類型·藥物類別·流通管道·各地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 市場概要
  • 市場成長要素
    • 研究資金的增加
    • 開發治療炭疽的新療法
  • 阻礙市場要素
    • 診斷治療相關的高成本
  • 波特的五力分析

第5章 市場細分化

  • 各炭疽病類型
    • 皮膚炭疽病
    • 肺炭疽病
    • 腸炭疽病
    • 注射炭疽病
  • 各藥物類別
    • 抗生素
    • 免疫球蛋白
    • 其他
  • 各流通管道
    • 醫院藥局
    • 零售藥局
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東·非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Altimune Inc.
    • Elusys Therapeutics, Inc.
    • Emergent BioSolutions, Inc.
    • Porton Biopharma
    • Merck & Co., Inc.
    • Novartis AG
    • GlaxoSmithKline PLC
    • Teva Pharmaceutical Industries Ltd.

第7章 市場機會及今後趨勢

目錄
Product Code: 67062

The anthrax treatment market will show rapid growth due to the increase in research funding and the development of novel therapies for the treatment of anthrax. The increasing public-private partnerships in order to facilitate the novel developments for the innovative and effective treatment of anthrax are also some of the factors expected to boost the growth of the anthrax treatment market.

There has been an increase in the development of novel therapies for anthrax due to the rising threat of exposure to Bacillus anthracis among civilian populations and military forces. Although clinical trials have been conducted to examine the safety and pharmacodynamics in humans, the efficacy studies are still inadequate. There are also novel antimicrobial strategies that are in the development to replace the antibiotics against anthrax bacilli.

The growing threat of exposure among the civilian population and military forces has thus led to the development of new therapies for anthrax treatment, which will make a positive impact on the growth of the global anthrax treatment market.

Key Market Trends

Cutaneous Anthrax Segment is Expected to Dominate the Anthrax Type Segment During the Forecast Period

By anthrax type, the market is segmented into cutaneous anthrax, inhalation anthrax, gastrointestinal anthrax and injection anthrax. It has been found that in most of the reported cases, the cutaneous anthrax is found to be the most common anthrax, that is accounting for more than 80 per cent of the cases. As per the European Centre for Disease Prevention and Control, nine cases of cutaneous anthrax were reported from Hungary in 2014. Moreover, the transmission from the gastrointestinal route has also seen rising with increasing consumption of raw uncooked meat. Thus all these factors are expected to drive the overall market.

North America is Anticipated to Dominate the Anthrax Treatment Market

North America has dominated the global market owing to high government funding, supportive strategies, and the presence of key players in this region. There are also factors such as initiatives by organizations like the CDC supporting the development of novel therapies for the treatment of anthrax drives market growth in the Americas.

Europe is also expected to dominate the anthrax treatment market due to the high prevalence of anthrax in the region. Asia Pacific is also an another leading region in terms of market growth as anthrax is one of the common endemics in China, and in recent years, several anthrax outbreaks have been reported in China.

Competitive Landscape

There has been a presence of a considerable number of companies developing vaccines and therapeutics. There has been a presence of several companies that is quite intense. Factors such as the increase in the development of new therapies and an increase in research funding will provide considerable growth opportunities to anthrax treatment manufactures.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increase in Research Funding
    • 4.2.2 Development of Novel Therapies for Treatment of Anthrax
  • 4.3 Market Restraints
    • 4.3.1 High Cost Associated with Diagnostic Treatment
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Anthrax Type
    • 5.1.1 Cutaneous Anthrax
    • 5.1.2 Inhalation Anthrax
    • 5.1.3 Gastrointestinal Anthrax
    • 5.1.4 Injection Anthrax
  • 5.2 By Drug Class
    • 5.2.1 Antibiotics
    • 5.2.2 Immunoglobulins
    • 5.2.3 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Altimune Inc.
    • 6.1.2 Elusys Therapeutics, Inc.
    • 6.1.3 Emergent BioSolutions, Inc.
    • 6.1.4 Porton Biopharma
    • 6.1.5 Pfizer Inc.
    • 6.1.6 Bayer AG
    • 6.1.7 GlaxoSmithKline plc
    • 6.1.8 Teva Pharmaceuticals
    • 6.1.9 Eli Lilly and Company

7 MARKET OPPORTUNITIES AND FUTURE TRENDS